Ritedose Pharmaceuticals Launches <em>Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)</em>
COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons
Ritedose Launches <em>Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL)</em> to Meet National Drug Shortage
COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose
Ritedose Reaches Milestone with Asset Purchase <br><em>Becomes largest generic drug maker of its kind</em>
COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.
Novo Holdings to acquire Ritedose: <br><em>Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.</em>
COPENHAGEN, Denmark, Jan. 4, 2022 /PRNewswire/ – Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines.
Recent Comments